Literature DB >> 11706814

A new diagnostic method for adenoma malignum and related lesions: latex agglutination test with a new monoclonal antibody, HIK1083.

K Ishii, T Kumagai, M Tozuka, H Ota, T Katsuyama, M Kurihara, T Shiozawa, H Noguchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11706814     DOI： 10.1016/s0009-8981(01)00611-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


× No keyword cloud information.
  5 in total

Review 1.  Endocervical glandular lesions: controversial aspects and ancillary techniques.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

2.  Clonality analysis suggests that STK11 gene mutations are involved in progression of lobular endocervical glandular hyperplasia (LEGH) to minimal deviation adenocarcinoma (MDA).

Authors:  Akiko Takatsu; Tsutomu Miyamoto; Chiho Fuseya; Akihisa Suzuki; Hiroyasu Kashima; Akiko Horiuchi; Keiko Ishii; Tanri Shiozawa
Journal:  Virchows Arch       Date:  2013-05-04       Impact factor: 4.064

3.  Utility of imaging modalities for predicting carcinogenesis in lobular endocervical glandular hyperplasia.

Authors:  Makiko Omori; Tetsuo Kondo; Hikaru Tagaya; Yumika Watanabe; Hiroko Fukasawa; Masataka Kawai; Kumiko Nakazawa; Akihiko Hashi; Shuji Hirata
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

4.  Limited frequency of malignant change in lobular endocervical glandular hyperplasia.

Authors:  Hisanori Kobara; Tsutomu Miyamoto; Hirofumi Ando; Ryoichi Asaka; Akiko Takatsu; Ayumi Ohya; Shiho Asaka; Tanri Shiozawa
Journal:  Int J Gynecol Cancer       Date:  2020-09-03       Impact factor: 3.437

5.  Usefulness of a management protocol for patients with cervical multicystic lesions: A retrospective analysis of 94 cases and the significance of GNAS mutation.

Authors:  Hirofumi Ando; Tsutomu Miyamoto; Hiroyasu Kashima; Akiko Takatsu; Keiko Ishii; Yasunari Fujinaga; Tanri Shiozawa
Journal:  J Obstet Gynaecol Res       Date:  2016-10-08       Impact factor: 1.730
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.